Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — 2023 J.P. Morgan Healthcare Conference
19 slides from Amneal Pharmaceuticals's conference presentation, Jan 10, 2023
Slide 1: Amneal Pharmaceuticals
Amneal Pharmaceuticals Chirag Patel, Co-founder and Co-CEO 2023 JPMorgan Healthcare Conference January 10, 2023 g
Slide 2: Cautionary Statement on Forward Looking Statements
Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements reg
Slide 3: Amneal Pharmaceuticals – We make healthy possible
Amneal Pharmaceuticals – We make healthy possible® • Amneal is an innovative essential medicines company with an expanding portfolio of complex generic, injectable, biosimilar and specialty therapies • Our R&D pipeline is highly productive – generating 20-30 new product launches per year, with key c
Slide 4: Our strategy for growth as a global essential medicines company
Our strategy for growth as a global essential medicines company Business area Strategy for growth Growth projection(1) Grow our top 5 U.S. Generics portfolio of 225+ products with 20-30 new Retail Low-single digit growth product launches each year and increasingly focused on complex areas Expand por
Slide 5: Amneal's commitment to innovation
Amneal’s commitment to innovation Biosimilars Illinois & Spain K-127 (Myasthenia Alymsys® Gravis) (bevacizumab) Releuko® DHE (filgrastim) (Migraine & Amneal founded Transdermal FyInetraTM Cluster Oral liquids Inserts / Implants Injectables patches New Jersey (pegfilgrastim) Headache) New Jersey New
Slide 6: Diversified, complex Generics portfolio that continues to grow
Diversified, complex Generics portfolio that continues to grow Continued mix shift to more complex portfolio Leading generics company Generics net revenues mix ($’s) Pipeline mix • Top 5 U.S. generics company (based on volume) (# of products) • Diverse 250+ product portfolio shifting towards more co
Slide 7: Our wheel of innovation in Generics keeps turning
Our wheel of innovation in Generics keeps turning Developing pipeline across increasingly complex dosage forms with 88% non-oral solids ~106 pipeline Oral Solids: 44 Injections: 31 Ophthal/Otic: 7 products with $19,461 $3,645 ~$45B TAM Pending $12,450 $2,944 ANDA’s $1,053 $259 $276 $48 $183 $659 $29
Slide 8: Scaling our injectables business to $300M+ revenue by 2025
Scaling our injectables business to $300M+ revenue by 2025 Expanding portfolio and infrastructure with key capabilities at 4 sites to drive injectables revenue growth • Targeting 30-40 launches from now to ✓ Across presentation formats: Vials, $ millions Prefilled Syringes (PFS), Cartridges, • Expec
Slide 9: Expect $200M+ peak sales from 1st 3 U.S. oncology biosimilars
Expect $200M+ peak sales from 1st 3 U.S. oncology biosimilars ~$4B TOTAL Estimated U.S. market size (1) for our first three U.S. approved ~$2B BIOSIMILARS oncology biosimilars U.S. Our biosimilars strategy: TM Alymsys® Releuko® Fylnetra biosimilars • Expanding portfolio through in-licensing where we
Slide 10: Expanding branded portfolio expected to drive growth
Expanding branded portfolio expected to drive growth Q3’22 LTM growth of existing products + New branded launches in the pipeline (1) + Business development $373M 2023 2024 2025 2026 • Pursue strategic, accretive IPX203 (Parkinson’s) transactions focused on • Focused in Neurology Rytary® DHE commerc
Slide 11: IPX203 is a novel, long-lasting formulation of extended-release CD/LD
IPX203 is a novel, long-lasting formulation of extended-release CD/LD that, if approved, would deliver more “Good On” time with fewer doses Parkinson’s disease (PD) overview Potential benefits of IPX203 Potential $300-500M peak sales ~1 million Innovative formulation Expect broader US patient popula
Slide 12: Entering select international markets with impactful products
Entering select international markets with impactful products (1) MARKET SIZE Q4 2022 Update Expect to be commercial in $197B 2025 • Signed long-term agreement with China by early 2023 with 5 products filed currently Orion to distribute Generic products $168B and more planned over time in Europe, Au
Slide 13: Strong durable performance driven by innovation and execution
Strong durable performance driven by innovation and execution Net revenue growth: +11% CAGR from 2019 to 2022 Adjusted EBITDA growth: +15% CAGR from 2019 to 2022 $ millions $ millions ~$2,200 $512 ~$510 * $2,094 $433 $1,993 $339 $1,626 (1) (2) 2019 Actual 2020 Actual 2021 Actual 2022 Guidance 2019 A
Slide 14: Capital allocation focused on driving long-term returns with a commitment to de-leverage
Capital allocation focused on driving long-term returns with a commitment to de-leverage over time $ millions September 30, 2022 Capital allocation priorities Current portion and long-term debt (1) $2,697 • Consistent investments in organic growth, specifically R&D, commercial and capital spend, to
Slide 15: Amneal key catalysts launches and ones ahead
Amneal key catalysts launches and ones ahead ✓ Q4’22 launches: include Clindamycin phosphate gel 1%, Ipratropium bromide nasal spray, and Prednisolone sodium phosphate oral solution Retail • 2023 planned launches include in Ophthalmics/Otics: gCiproDex®, Fluorometholone acetate, gRestasis®, and gPre
Slide 16: Key takeaways for Amneal Pharmaceuticals at the 2023 JPM Healthcare Conference
Key takeaways for Amneal Pharmaceuticals at the 2023 JPM Healthcare Conference Execution • Focused on driving organic growth with an of strategy expanding portfolio of complex generics, on-track injectables, biosimilars and specialty products • 26 generic new product launches in 2022 and Key catalys
Slide 17: We make healthy possible
2 Yamneal We make healthy possible®
Slide 18: Appendix: Non-GAAP Reconciliations
Appendix: Non-GAAP Reconciliations
Slide 19: Reconciliation of net (loss) income to adjusted EBITDA
Reconciliation of net (loss) income to adjusted EBITDA ($) in millions Trailing-12 Months Year Ended September 30, December 31, 2022 2021 2020 2019 Net (loss) income $ (269.4) $ 20.2 $ 68.6 $ (603.6) Adjusted to add: Interest expense, net 145.3 136.3 146.0 168.2 Provision for (benefit from) income t
Amneal Pharmaceuticals — 2023 J.P. Morgan Healthcare Conference on 6ix